NCT03792841 Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC Status TERMINATED Phase PHASE1
NCT03792347 Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus Status COMPLETED Phase PHASE1
NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03776864 Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Status TERMINATED Phase PHASE2
NCT03776136 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) Status COMPLETED Phase PHASE2
NCT03775850 A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Status COMPLETED Phase PHASE1
NCT03774732 PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03773744 MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma Status WITHDRAWN Phase PHASE1
NCT03771820 Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen Status UNKNOWN Phase PHASE2
NCT03769467 Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Status TERMINATED Phase PHASE1/PHASE2
NCT03769129 Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC Status RECRUITING Phase NA
NCT03768063 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03765229 An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma Status COMPLETED Phase PHASE2
NCT03761914 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Status COMPLETED Phase PHASE1/PHASE2
NCT03760575 Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) Status RECRUITING Phase PHASE1
NCT03757689 Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03753659 IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Status COMPLETED Phase PHASE2